TigerElec After-Hours Trading Surge: Is it a Real Opportunity? On August 29, 2025, TigerElec experienced a significant surge in after-hours trading. Institutional investors purchased ₩2.1 billion worth of shares, while foreign investors sold ₩0.23 billion. Has the company’s return to profitability created a genuine opportunity, or are there hidden risks lurking beneath the surface? This … Read more
DSR Steel’s Q2 2025 Earnings: A Remarkable Turnaround DSR Steel has announced a significant return to profitability in Q2 2025, exceeding market expectations. This impressive performance was driven by a combination of factors, including the successful integration of its Vietnam subsidiary and continued strength in its core business segments. This article provides a detailed analysis … Read more
Ubcare: A Mixed Bag of Profit and Declining Revenue Digital healthcare leader Ubcare has returned to profitability in Q2 2025, posting a positive operating profit. However, the celebration is tempered by concerns over the continued decline in consolidated revenue. This article analyzes Ubcare’s Q2 earnings and IR presentation, examining the factors behind both the return … Read more
Cellomax Science at a Crossroads: Growth vs. Decline – Where’s the Investment Opportunity? Cellomax Science has shown steady growth alongside the expanding health functional food market. However, their recently released H1 2025 report reveals mixed signals of growth and slowdown, leaving investors with a difficult decision. This analysis provides an in-depth look at Cellomax Science’s … Read more
JPI Healthcare: Emerging from the Red? Newly listed on the KOSDAQ in August 2025, JPI Healthcare has caught investors’ attention with a Q2 earnings surprise. Is this turnaround sustainable, or just a fleeting moment? This article dives into JPI Healthcare’s performance, analyzes its investment potential, and provides key insights for investors. 1. About JPI Healthcare … Read more
ISU Abxis: A True Turnaround Story? ISU Abxis recently announced a return to profitability in its H1 2025 report, sparking optimism for a turnaround. However, the company’s true potential hinges on its future strategy, set to be unveiled at the IR on August 25th. This article provides investors with key insights into ISU Abxis’s current … Read more
Nature & Environment Raises ₩2 Billion: Opportunity or Risk? Nature & Environment, fresh off a profitable first half of 2025, has announced the issuance of ₩2 billion in convertible bonds. What does this new funding mean for the company’s future? This article analyzes the background and purpose of the bond issuance, highlighting key considerations for … Read more
A Glimpse into the Future of Gaonchips, the AI Chip Design Expert! Gaonchips, a leader in next-generation semiconductor technology, is holding an Investor Relations (IR) session on August 20, 2025. Following remarkable 51.72% revenue growth in 2024, Gaonchips is addressing the challenge of profitability slowdown. This IR is expected to provide answers to investors’ questions … Read more
Can DoubleU Games Successfully Transition to Casual Games? Social casino giant DoubleU Games held its investor relations (IR) presentation on August 26, 2025. Following the acquisition of Paxie Games, DoubleU Games announced its diversification strategy and entry into the casual games market. However, slowing profit growth and foreign exchange volatility present significant challenges. This IR … Read more
Prestige BioPharma Takes Flight with European Market Entry! Prestige BioPharma’s Tuznue (HD201) has received European approval, marking a significant milestone and propelling the company to profitability. This achievement validates Prestige BioPharma’s competitiveness in the global biopharmaceutical market. This report provides an in-depth analysis of the Q3 2025 results and recent announcements, offering valuable insights into … Read more